Hypofractionated Radiotherapy for Lung Cancer

Phase 1

Completed

• Conditions: Lung Cancer

• Registration Number: NCT00214123
• Lead Sponsor: University of Wisconsin, Madison

Brief Summary

The purpose of this trial is to pilot reducing the duration of radiation treatment for lung cancer patients from 6 to 5 weeks using tomotherapy. Specific patient doses will be based on tumor volume being treated. Modeling has shown that increased biologically effective dose (BED) to tumors can be achieved by shortening the radiation delivery schedule and increasing the dose per fraction. This requires decreasing the total dose to hold lung toxicity constant at each dose per fraction level. This is a major paradigm shift in the treatment in this disease and is projected to result in significant improvements in patient outcome as well as a substantial cost savings.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-06
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-21
• Primary Completion: 2012-12
• Study Completion: 2012-12
• Status Verified: 2015-07
• Last Update Submitted: 2019-12-12
• Last Update Posted: 2019-12-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 79

Inclusion Criteria

• Thoracic neoplasm requiring at lest 60 Gy conventional radiotherapy

Exclusion Criteria

• Prior bleomycin or gemcitabine chemotherapy
• Prior thoracic radiotherapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Grade 3 pneumonitis lasting greater than 2 weeks	90 days post radiotherapy (XRT)

Trial Locations

Locations (1)

University of Wisconsin Hospital and Clinics; 🇺🇸 Madison, Wisconsin, United States